Quality of Life research assesses the impact of the disease and its treatments on patients’ overall well-being.
In oncological and hematological diseases, treatment is evaluated not only for clinical effectiveness but also for its physical, psychological, social, and relational impact.
Through validated tools and specific questionnaires, quality of life (QoL) research measures symptoms (such as pain, fatigue, or nausea), daily functioning, emotional state, and individuals’ subjective perception of their health status. This approach makes it possible to integrate clinical data with the patient’s direct experience, promoting an increasingly person-centered approach to medicine.
In the oncological and hematological fields, the study of QoL is now an integral part of clinical trials and treatment evaluations, as it helps guide care decisions toward therapies that are not only effective but also sustainable over time for those who experience them.
Quality of Life and Patient-Reported Outcomes (PRO)
In recent decades, significant progress has been made across various areas of hematological diseases. Future prospects are promising, driven by advances in diagnostic methods and the development of novel therapies. However, clinicians and patients are now often faced with complex therapeutic choices among options that offer similar clinical efficacy and safety profiles. As a result, medical decision-making has become more nuanced and requires a more patient-centered approach.
Traditionally, hematologists have focused on laboratory measures and clinical parameters; however, there is now strong evidence that health status information reported directly by patients provides clinically relevant data that cannot be captured through the standard measures used in clinical research.
Integrating the patient’s perspective into oncological care is possible through Patient-Reported Outcomes (PROs), defined by the U.S. Food and Drug Administration as “any report of the status of a patient’s health condition that comes directly from the
patient, without interpretation of the patient’s response by a clinician or anyone else”.
Quality of life assessments and symptom burden evaluations, reported directly by patients, are well-known examples of key PROs and are widely used in hematology.
Evidence demonstrating the added value of integrating PROs into clinical research and routine care is increasingly growing in the field of hematology. It has been shown that PROs help to better understand the impact of disease and treatments across various hematological malignancies. It has also been observed that they have independent prognostic value compared with clinical outcomes such as survival.